CSN Login
Members Online: 8

You are here

Great news!

CSN is getting an upgrade. All of your posts will still be here, but the website will have a new look, new features and be mobile-friendly. To prepare for the changes, the site will be down briefly at the end November. We’ll continue to provide updates as we get closer.    

POLE ultra-mutated endometrial cancer and immunotherapy

Posts: 316
Joined: Oct 2017


In addition to tumours that have Micro Satellite Instability, it seems tumours that have the POLE exonuclease domain mutations are also good candidates for immunotherapy. If the genomic profiling of your tumour indicated the POLE mutation and you are experiencing a recurrence please check with your doctor to see if immunotherapy could be an option for you.

Here are a few papers that you might find interesting:


Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?



Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.


Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine



On tumor mutational burden and its ability predict response to immunotherapy



Subscribe to Comments for "POLE ultra-mutated endometrial cancer and immunotherapy"